Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa
The Journal of Infectious Diseases · 18.02.2026 · 233 (2) · e541-e549
DOI: 10.1093/infdis/jiaf585 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 17.11.2025. Verfasst von Clayton W Hall und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, beta-Lactamase Inhibitors, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Ceftazidime-avibactam (CZA), ceftolozane-tazobactam (CT), and imipenem-relebactam (IMR) are newer β-lactam/β-lactamase inhibitor (BL/BLI) combinations used for treatment of multidrug resistant (MDR) Pseudomonas aeruginosa, although resistance has already emerged. Optimal use of these agents relies on timely, accurate susceptibility testing results and understanding of local resistance mechanisms.
Methods
183 MDR P. aeruginosa clinical isolates were used to evaluate the performance of commercial Sensititre and Phoenix panels for CZA, CT, and IMR susceptibility testing compared to broth microdilution (BMD). Genomic resistance determinants were also predicted for each isolate with AMRFinderPlus.
Results
Categorical agreement (CA) of the Sensititre panel compared to BMD was 95.8%, 90.1%, and 95.8% for CZA, CT, and IMR, respectively. CA of the Phoenix panel was 83.0% for CZA and 85.7% for CT. The Phoenix panel was biased toward under-calling CZA resistance while error rates were acceptable for CT by the error-rate-bound method. AMRFinderPlus identified acquired β-lactamases in 4.6% of first-time patient isolates. CA of genotype with BMD was 74.9% for CZA, 91.9% for CT, and 90.7% for IMR. However, all agents had unacceptably high VME rates using genotypic testing because many phenotypically resistant isolates had no identifiable genotypic resistance determinants.
Conclusions
The Sensititre panel met standard acceptance criteria while the Phoenix panel had low CA for all tested BL/BLIs compared to BMD. Acquired β-lactamases were a rare cause of BL/BLI resistance. Further understanding of resistance mechanisms is required before phenotypic BL/BLI resistance can be reliably predicted from genotype, especially in settings where prevalence of acquired β-lactamases is low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
- Shared Hospital Laboratory, Toronto, ON, Canada.
- Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
- Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
- Faculty of Computer Science, Dalhousie University, Halifax, NS, Canada.
ORCID-Profile: Clayton W Hall, Nicholas Waglechner, Erin Choi, Finlay Maguire
Zitieren
APA
Hall, C. W., Waglechner, N., Choi, E., Aftanas, P., Katz, K., Vermeiren, C., Maguire, F., Kozak, R., & Li, X. X. (2026). Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa. The Journal of Infectious Diseases, 233(2), e541-e549. https://doi.org/10.1093/infdis/jiaf585
Vancouver
Hall CW, Waglechner N, Choi E, Aftanas P, Katz K, Vermeiren C, et al. Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa. The Journal of Infectious Diseases. 2026;233(2):e541-e549. doi:10.1093/infdis/jiaf585
BibTeX
@article{Hall2026,
author = {Hall, Clayton W and Waglechner, Nicholas and Choi, Erin and Aftanas, Patryk and Katz, Kevin and Vermeiren, Christie and Maguire, Finlay and Kozak, Robert and Li, Xena X},
title = {Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {233},
number = {2},
pages = {e541--e549},
doi = {10.1093/infdis/jiaf585}
}
EUVIMED